ALK-abello A/S Class B (AKBLF)
OTHER OTC:AKBLF
Want to see AKBLF full AI Analyst Report?
Earnings Data
Report Date
Aug 20, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.23Last Year’s EPS
0.19Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive: the company delivered strong Q1 financial results (18% revenue growth, 22% EBIT growth, 32% EBIT margin), achieved a major tablet sales milestone (over DKK 1 billion in a quarter), upgraded full-year guidance, reported robust regional and anaphylaxis product growth, and announced a successful Phase II peanut trial and key neffy regulatory approvals. Notable challenges include higher capacity costs (+23%), international shipment phasing (notably Japan) causing a -17% tablet decline in some markets, partner-related lower-margin revenue expected to rise, neffy market-access hurdles (UK local formularies, U.S. access), potential German pricing/rebate risk, and planned increased R&D/commercial spending for upcoming phases. Overall, the positives materially outweigh the negatives given upgraded guidance, cash generation, and strategic clinical progress.Company Guidance
Revenue and EBIT Growth
Revenue increased 18% in local currencies to DKK 1.8 billion; operating profit (EBIT) grew 22% to DKK 570 million, lifting the EBIT margin to 32% (from 31%).
Tablet Sales Milestone
For the first time, total tablet sales exceeded DKK 1 billion in a single quarter; tablet sales grew ~26% in Europe and 26% in North America in Q1.
Improved Gross Margin and Cash Generation
Gross margin improved to 69% (+2 percentage points) driven by higher volumes and product mix; cash flow from operating activities was DKK 761 million and free cash flow DKK 671 million.
Upgraded Full-Year Guidance
Full-year revenue outlook upgraded to 13%–16% growth in local currencies (from 11%–15%); EBIT margin outlook upgraded to around 26%.
Strong Regional Performance — Europe & North America
Europe revenue up 19% with high double-digit tablet growth in Germany and France; North America revenue up 16% in local currencies driven by tablet demand in Canada and U.S. support from neffy co-promotion arrangements.
Anaphylaxis and Other Product Strength
Sales of anaphylaxis and other products increased 31% overall; anaphylaxis-only sales up 84%, with Jext benefiting from higher replacement rates and tender wins.
Peanut Allergy Phase II Success
Phase II ALLIANCE trial showed dose-dependent, statistically significant efficacy across multiple endpoints after 6 months; safe and well tolerated with low discontinuation and no treatment-related anaphylaxis/serious adverse events — Phase III expected late 2026 (FDA Fast Track designated).
Regulatory Progress for EURneffy
European Commission approved 1 mg EURneffy for children (4+ years, 15–30 kg); Canada approved 2 mg in April — first launches expected in H2 2026 and post-summer respectively; UK legislative push (schools) supports future uptake.
Product Launch Rollouts and Prescriber Adoption
Pediatric tablet launched in majority of key European and North American geographies (house-dust-mite in 21 markets, tree pollen in 13); >4,000 prescribers in directly served markets have prescribed children’s tablets, with ~20% new to ALK.
AKBLF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AKBLF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 04, 2026 | $37.85 | $40.50 | +7.00% |
Feb 20, 2026 | $33.96 | $33.52 | -1.32% |
Nov 12, 2025 | $31.75 | $32.80 | +3.28% |
Aug 21, 2025 | $29.25 | $30.32 | +3.65% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ALK-abello A/S Class B (AKBLF) report earnings?
ALK-abello A/S Class B (AKBLF) is schdueled to report earning on Aug 20, 2026, TBA (Confirmed).
What is ALK-abello A/S Class B (AKBLF) earnings time?
ALK-abello A/S Class B (AKBLF) earnings time is at Aug 20, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKBLF EPS forecast?
AKBLF EPS forecast for the fiscal quarter 2026 (Q2) is 0.23.